Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

TAK – Takeda Pharmaceutical Company Limited

Float Short %

Margin Of Safety %

24

Put/Call OI Ratio

0.07

EPS Next Q Diff

EPS Last/This Y

129.68

EPS This/Next Y

32.08

Price

15.52

Target Price

16.87

Analyst Recom

2.06

Performance Q

7.7

Relative Volume

1.02

Beta

0.25

Ticker: TAK




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25TAK14.470.090.161543
2025-07-28TAK14.310.090.001550
2025-07-29TAK14.310.090.001575
2025-07-30TAK13.60.090.291601
2025-07-31TAK13.720.160.382385
2025-08-01TAK14.160.160.562429
2025-08-04TAK14.270.160.792411
2025-08-05TAK14.20.160.002432
2025-08-06TAK14.270.160.002433
2025-08-07TAK14.360.160.002437
2025-08-08TAK14.450.160.772438
2025-08-11TAK14.420.160.292449
2025-08-12TAK14.640.150.002435
2025-08-13TAK14.770.120.522919
2025-08-14TAK14.810.120.002932
2025-08-15TAK150.120.002935
2025-08-18TAK15.190.120.012735
2025-08-19TAK15.20.110.012915
2025-08-20TAK15.480.110.403019
2025-08-21TAK15.30.110.003060
2025-08-22TAK15.520.070.004607
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25TAK14.48- 1191.60.00
2025-07-28TAK14.31- 1179.00.00
2025-07-29TAK14.32- 1190.20.00
2025-07-30TAK13.60- 1095.50.00
2025-07-31TAK13.72- 1171.10.00
2025-08-01TAK14.16- 869.00.00
2025-08-04TAK14.26- 735.50.00
2025-08-05TAK14.20- 712.70.00
2025-08-06TAK14.28- 768.70.00
2025-08-07TAK14.36- 768.00.00
2025-08-08TAK14.44- 783.90.00
2025-08-11TAK14.42- 764.10.00
2025-08-12TAK14.64- 795.40.00
2025-08-13TAK14.77- 775.30.00
2025-08-14TAK14.81- 774.50.00
2025-08-15TAK15.00- 797.60.00
2025-08-18TAK15.19- 803.70.00
2025-08-19TAK15.20- 768.60.00
2025-08-20TAK15.48- 795.1129.91
2025-08-21TAK15.30- 746.6129.91
2025-08-22TAK15.52- 790.7129.91
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25TAK0.003.150.14
2025-07-28TAK0.002.590.14
2025-07-29TAK0.002.590.14
2025-07-30TAK0.002.590.14
2025-07-31TAK0.002.590.14
2025-08-01TAK0.002.590.15
2025-08-04TAK0.002.780.15
2025-08-05TAK0.002.780.15
2025-08-06TAK0.002.780.15
2025-08-07TAK0.002.780.15
2025-08-08TAK0.002.780.15
2025-08-11TAK0.002.750.15
2025-08-12TAK0.002.750.26
2025-08-13TAK0.002.750.26
2025-08-14TAK0.002.750.26
2025-08-15TAK02.750.26
2025-08-18TAK03.680.26
2025-08-19TAK03.680.26
2025-08-20TAK03.680.26
2025-08-21TAK03.680.26
2025-08-22TAK03.680
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

3.68

Beta

0.25

Average Sales Estimate Current Quarter

1171870

Average Sales Estimate Next Quarter

1183180

Fair Value

19.27

Quality Score

63

Growth Score

81

Sentiment Score

92

Actual DrawDown %

22.3

Max Drawdown 5-Year %

-31.4

Target Price

16.87

P/E

52.49

Forward P/E

24.05

PEG

1.17

P/S

1.62

P/B

1.02

P/Free Cash Flow

8.97

EPS

0.3

Average EPS Est. Cur. Y​

129.91

EPS Next Y. (Est.)

161.99

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.19

Relative Volume

1.02

Return on Equity vs Sector %

-22.7

Return on Equity vs Industry %

-5.8

EPS 1 7Days Diff

-7.5

EPS 1 30Days Diff

33.36

EBIT Estimation

790.7
Takeda Pharmaceutical Company L
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 47455
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
stock quote shares TAK – Takeda Pharmaceutical Company Limited Stock Price stock today
news today TAK – Takeda Pharmaceutical Company Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TAK – Takeda Pharmaceutical Company Limited yahoo finance google finance
stock history TAK – Takeda Pharmaceutical Company Limited invest stock market
stock prices TAK premarket after hours
ticker TAK fair value insiders trading